In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) ...
Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases. Its founders include ...
With the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it came to light that there were no specific and highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results